Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myeloid, Acute 19Precursor Cell Lymphoblastic Leukemia-Lymphoma 17Primary Myelofibrosis 12Polycythemia Vera 11Myelodysplastic Syndromes 10Leukemia 10Leukemia, Myelogenous, Chronic, BCR-ABL Positive 9Myeloproliferative Disorders 8Recurrence 6Leukemia, Myelomonocytic, Chronic 6Hematologic Neoplasms 6Breast Neoplasms 6Myelodysplastic-Myeloproliferative Diseases 5Lymphoma, T-Cell 5Leukemia, Lymphocytic, Chronic, B-Cell 5Hodgkin Disease 5Graft vs Host Disease 5Thrombocythemia, Essential 4Leukemia, Myeloid, Chronic-Phase 4Triple Negative Breast Neoplasms 3Prostatic Neoplasms 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Multiple Myeloma 3Lymphoma, T-Cell, Cutaneous 3Lymphoma, Non-Hodgkin 3Lymphoma 3Leukemia, Prolymphocytic, T-Cell 3Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 3Squamous Cell Carcinoma of Head and Neck 2Pancreatic Neoplasms 2

Interventions

ruxolitinib 1Motivational Interviewing 1Advance Care Planning 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Other Cancer × ruxolitinib × Clear all
NCT03674047 2025-11-10

Ruxolitinib for Bronchiolitis Obliterans Syndrome (BOS) After Allogeneic Hematopoietic Cell Transplantation (HCT)

Massachusetts General Hospital

Phase 2 Active not recruiting
50 enrolled

Other Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡